Payment overview · 2025
General Payments
$78.49
5 reported records · 3 companies
Healthcare provider profile · identity verified
Euna Ann Roop, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · SOUTH WILLIAMSON, KY · NPI 1942774708
Verified facts
What the public records show
CMS Open Payments records show Euna Ann Roop, APRN received $78.49 in general payments during 2025 across 5 reported records.
Merck Sharp & Dohme LLC accounted for 50.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $39.36 | 50.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.46 | 32.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.67 | 17.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $78.49 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $39.36 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.46 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 413 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 349 | 60 |
| Lisinopril | Lisinopril | 306 | 70 |
| Methylprednisolone | Methylprednisolone | 303 | 174 |
| Gabapentin | Gabapentin | 277 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 257 | 52 |
| Metformin Hcl | Metformin Hcl | 255 | 47 |
| Montelukast Sodium | Montelukast Sodium | 237 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 234 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 223 | 41 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 217 | 48 |
| Omeprazole | Omeprazole | 209 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 199 | 41 |
| Losartan Potassium | Losartan Potassium | 141 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 141 | 35 |
| Potassium Chloride | Potassium Chloride | 137 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 29 |
| Furosemide | Furosemide | 120 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 113 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 106 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 41 |
| Meloxicam | Meloxicam | 104 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 102 | 80 |
| Cefdinir | Cefdinir | 94 | 72 |
| Buspirone Hcl | Buspirone Hcl | 93 | 25 |
| Sertraline Hcl | Sertraline Hcl | 92 | 22 |
| Ibuprofen | Ibuprofen | 90 | 27 |
| Carvedilol | Carvedilol | 87 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 19 |
| Prednisone | Prednisone | 82 | 48 |
| Fluconazole | Fluconazole | 80 | 49 |
| Lovastatin | Lovastatin | 80 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 41 |
| Amoxicillin | Amoxicillin | 72 | 58 |
| Ropinirole Hcl | Ropinirole Hcl | 72 | 17 |
| Glipizide Er | Glipizide | 70 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 20 |
| Ozempic | Semaglutide | 67 | 13 |
| Azithromycin | Azithromycin | 66 | 53 |
| Fenofibrate | Fenofibrate | 65 | 13 |
| Famotidine | Famotidine | 61 | 15 |
| Atenolol | Atenolol | 60 | suppressed |
| Simvastatin | Simvastatin | 60 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 57 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 16 |
| Trulicity | Dulaglutide | 55 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 53 | 12 |
| Glipizide | Glipizide | 53 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 17 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 46 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 46 | 14 |
| Spironolactone | Spironolactone | 46 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 46 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 45 | suppressed |
| Ofloxacin | Ofloxacin | 44 | 29 |
| Jardiance | Empagliflozin | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 16 |
| Vascepa | Icosapent Ethyl | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 37 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Lansoprazole | Lansoprazole | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | 17 |
| Ondansetron Odt | Ondansetron | 35 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 20 |
| Eliquis | Apixaban | 28 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Glyburide | Glyburide | 28 | suppressed |
| Cephalexin | Cephalexin | 26 | 24 |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 11 |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Armour Thyroid | Thyroid,pork | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Nystatin | Nystatin | 16 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Perindopril Erbumine | Perindopril Erbumine | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Glipizide Xl | Glipizide | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $78.49 · 5 records | Merck Sharp & Dohme LLC | MOUNJARO, VERQUVO, VOQUEZNA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error